What cardiac assessment/clearance is required before initiating romosozumab (generic name) therapy for osteoporosis?

Cardiac Assessment Before Romosozumab Initiation

Romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding 12 months, and patients at high cardiovascular risk require careful evaluation before starting therapy. 1

Contraindications Based on Cardiac History

The FDA black-box warning and major clinical guidelines establish clear cardiac contraindications:

• Absolute contraindication: Recent MI or stroke (within 1 year) 1
• Relative contraindication: High cardiovascular risk patients 2

The 2020 AACE/ACE guidelines explicitly state that romosozumab carries a black-box warning prohibiting use in patients with high cardiovascular event risk or recent MI/stroke 1. This stems from the ARCH trial (N=4,093), which demonstrated significantly more serious cardiovascular events with romosozumab compared to alendronate, though this risk was small and did not persist beyond the treatment period 1.

Required Pre-Treatment Cardiac Evaluation

Before prescribing romosozumab, clinicians must:

1. Document cardiovascular history including:

   • Prior MI or stroke (timing is critical—must be >12 months ago)
   • Coronary artery disease
   • Peripheral vascular disease
   • Heart failure
   • Atrial fibrillation
   • Hypertension status

2. Assess cardiovascular risk factors:

   • Diabetes mellitus
   • Hyperlipidemia
   • Smoking status
   • Family history of premature cardiovascular disease

3. No formal cardiac clearance or testing is mandated by guidelines, but clinical judgment should guide whether additional workup (ECG, echocardiogram, stress testing, or cardiology consultation) is warranted in borderline cases.

Risk Stratification by Patient Population

The 2022 ACR glucocorticoid-induced osteoporosis guidelines provide specific recommendations by fracture risk level 2:

• Moderate fracture risk: Conditionally recommend against romosozumab due to MI, stroke, or death risk 2
• High or very high fracture risk: Conditionally recommend romosozumab only in patients intolerant of other agents 2
• Adults <40 years: Conditionally recommend against romosozumab due to cardiovascular risks 2
• Solid organ transplant patients: Conditionally recommend against romosozumab due to cardiovascular risks 2

Evidence Regarding Cardiovascular Safety

The cardiovascular safety data remains somewhat conflicting:

• ARCH trial concern: Increased serious cardiovascular events versus alendronate (though risk was small and transient) 1
• FRAME trial: Larger trial (N=7,180) comparing romosozumab to placebo showed no persistent cardiovascular signal 1
• Recent real-world data (2025): Some studies suggest romosozumab may actually have fewer cardiovascular events than PTH analogues 3, while others show no increased MACE during treatment 4
• Meta-analysis findings: Romosozumab increased 4-point MACE (1.39,95% CI 1.01-1.90) but not 3-point MACE 5

Common Pitfalls to Avoid

1. Don't assume "no cardiac history" equals low risk: Actively screen for cardiovascular risk factors and calculate risk if uncertain
2. Don't prescribe within 12 months of MI/stroke: This violates the black-box warning
3. Don't overlook alternative therapies: For patients with cardiovascular concerns, bisphosphonates, denosumab, or PTH analogues may be safer first-line options 2
4. Don't forget sequential therapy: Romosozumab must be followed by antiresorptive therapy (bisphosphonate or denosumab) to maintain benefits 1

Practical Algorithm for Cardiac Assessment

Step 1: Review medical history for MI/stroke in past 12 months → If YES, do not prescribe

Step 2: Assess cardiovascular risk factors (diabetes, hypertension, CAD, smoking, hyperlipidemia) → If multiple risk factors present, consider alternative therapy

Step 3: If cardiovascular risk is low-moderate AND fracture risk is very high AND patient has failed/is intolerant to other therapies → Romosozumab may be appropriate

Step 4: Document informed consent discussion about cardiovascular risks versus fracture benefits

The decision ultimately weighs the substantial fracture reduction benefits (73% vertebral fracture reduction vs placebo, 38% hip fracture reduction) 1 against uncertain but potentially increased cardiovascular risk in a patient-specific context.